Innova Captab Limited · NSE:INNOVACAP
Innova Captab — Q1 FY25 Earnings Presentation
55 slides from Innova Captab's earnings presentation, Aug 9, 2024
Slide 1: Intimation of Investor Presentation for quarter ended June 30, 2024
INNOVA CAPTAB LIMITED 1281/1, Hilltop Industrial Estate, Near EPIP, Phase-I, Jharmajri, Baddi, Dist. Solan (H.P.)-173205 India. Phone: +91-1795-650820 August 09, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mumba
Slide 2: Q1 FY25 Investor Presentation
Investor Presentation Q1 FY25 Investor Presentation
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Q1FY25 Performance Highlights
Q1FY25 Performance Highlights
Slide 5: MD's Commentary
Performance Highlights 04 MD’s Commentary “For Q1FY25, we reported a total income of Rs 296 crores, a 27% growth compared to same quarter previous year. All business areas are experiencing healthy growth and are expected to maintain this momentum in the coming quarters. Our greenfield plant in Jammu
Slide 6: Financial Highlights
Performance Highlights 05 Financial Highlights Revenue from Operations EBITDA and EBITDA Margin1 PAT and PAT Margin (In Rs Crs) 13.9% 16.7% 15.1% 7.5% 10.9% 10.0% 294.3 262.6 44.3 29.5 43.6 28.7 233.2 32.4 17.6 Q1 FY24 Q4 FY24* Q1 FY25* Q1 FY24 Q4 FY24* Q1 FY25* Q1 FY24 Q4 FY24* Q1 FY25* Geographic
Slide 7: Quarterly Consolidated Profit & Loss Statement
Performance Highlights 06 Quarterly Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) Q1 FY25* Q1 FY24 YoY Q4 FY24* QoQ Revenue from Operations 294.3 233.2 262.6 Other Income 2.1 1.1 5.7 Total Income 296.4 234.4 26.5% 268.3 10.5% Cost of Material Consumed 199.2 166.5 168.3 Employee Cost
Slide 8: Corporate Snapshot
Corporate Snapshot
Slide 9: Innova Captab – At a Glance
Corporate Snapshot 08 Innova Captab – At a Glance Integrated Pharmaceutical Company in India with Presence Across the Pharmaceutical Value Chain 1 Contract Development and Manufacturing 4 Manufacturing Units 190+ 2 Baddi | 1 Dehradun | 1 Taloja CDMO Customers Business 2 Domestic Branded Generics Are
Slide 10: The Evolution
Corporate Snapshot 09 The Evolution Major Events and Milestones 1993 2006 1995 2010 2003 20132005 ▪ Established first manufacturing ▪ Commenced operations at a new ▪ Received GMP Certificate for cephalosporin plant in Baddi, Himachal Pradesh dedicated Cephalosporin block (“C products from the Minist
Slide 11: Key Strengths
Key Strengths
Slide 12: Key Strengths
11 Key Strengths Diversified Product Portfolio 01 04 R&D Centric Organization Deep Engagement with 02 Clients 05 Experienced Promoters and Management Team State of the Art Manufacturing Capabilities 03 06 Consistent Financial Performance
Slide 13: 1. Diversified Product Portfolio
Key Strengths 12 1. Diversified Product Portfolio Presence Across the Pharmaceuticals Value Chain Including Manufacturing, Distribution, Marketing and Exports CDMO Services and Products Domestic Branded Generics Sharon Bio Medicine Ltd • Comprehensive CDMO Formulation capabilities offering • Consist
Slide 14: 2. Deep Engagement with Clients
Key Strengths 13 2. Deep Engagement with Clients Developed Strong Relationships across the Indian Pharmaceutical Industry Revenue from CDMO Revenue from CDMO Revenue from CDMO Number of CDMO Revenue from CDMO Customers > 10 customers with customers < 5 Customers years relationship1 5-10 years1 years
Slide 15: 3. State of the Art Manufacturing Capabilities
Key Strengths 14 3. State of the Art Manufacturing Capabilities Our Manufacturing Capacity Helps Us to Provide Customers with Large Volumes and Satisfy their Requirements Second highest Fixed Asset Turnover ratio Ranked third among CDMO players in terms of tablet and and ROCE among the CDMO formulat
Slide 16: 3. Long Runway of Growth
Key Strengths 15 3. Long Runway of Growth Baddi Plant Dehradun | Taloja Plant Greenfield project at Jammu Capacity 45% - 50% Utilization 50% -60% FY24 revenue Un-utilized Optimum FY24 revenue Un-utilized Optimum Utilization FY23 FY25- to Rampup- 2-4 Optimum Rs 865 crs Utilization in Rs 190 crs* in c
Slide 17: 4. R&D Centric Organization
Key Strengths 16 4. R&D Centric Organization R&D is Critical to Maintaining Our Competitive Position and Addressing Changing Consumer and Industry Trends Dedicated R&D laboratory and pilot equipment located at Baddi, Himachal Pradesh which is 1 recognized by the DSIR for in-house R&D work Equipped w
Slide 18: 5. Experienced Promoters and Management Team
Key Strengths 17 5. Experienced Promoters and Management Team Qualified and Experienced Management Team Manoj Kumar Lohariwala Vinay Kumar Lohariwala Jayant Vasudeo Rao Archit Aggarwal Chairman & Whole-time Director Managing Director Whole-time Director Non-Executive Director • Bachelor’s in Commerc
Slide 19: 6. Consistent Financial Performance
Key Strengths 18 6. Consistent Financial Performance Strong Financial Performance with Visible Growth Profile Revenue from operations EBITDA and EBITDA Margin PAT and PAT Margin 13.6% 12.4% 13.3% 15.4% 8.4% 8.0% 7.3% 8.7% 1,081 926 167 94 801 123 68 64 99 411 56 35 FY21 FY22 FY23 FY24 FY21 FY22 FY23
Slide 20: Growth Strategies
Growth Strategies
Slide 21: Key Growth Strategies
Growth Strategies 20 Key Growth Strategies ▪ Establishing Cephalosporin, Penicillin, Penum & BFS blocks to manufacture Tablets, Capsules, Dry Powder Injection, Dry Syrup & BFS at new Greenfield Expansion at Jammu greenfield site in Jammu. Anticipate benefitting from the New Central Sector Scheme for
Slide 22: Historical Financial Highlights
Historical Financial Highlights
Slide 23: Consolidated Profit & Loss Statement
Historical Financial Highlights 22 Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) FY24 FY23 FY22 FY21 Revenue from Operations 1,081.3 926.4 800.5 410.7 Other Income 12.5 9.2 2.9 1.4 Total Revenue 1,093.8 935.6 803.4 412.0 Cost of Materials Consumed 728.3 691.6 617.9 310.7 Employee Co
Slide 24: Consolidated Balance Sheet
Historical Financial Highlights 23 Consolidated Balance Sheet Assets (Rs. Crs) FY24 FY23 FY22 FY21 Equity & Liabilities (Rs. Crs) FY24 FY23 FY22 FY21 Non - Current Assets 741.1 261.9 196.4 99.1 Total Equity 830.9 276.5 208.6 144.8 Property, plant and equipment 291.6 150.1 156.6 76.4 Share Capital 57
Slide 25: Cash Flow Statement
Historical Financial Highlights 24 Cash Flow Statement Particulars (Rs. Crs) FY24 FY23 FY22 FY21 Net Profit Before Tax 129.5 91.8 85.7 46.3 Adjustments for: Non -Cash Items / Other Investment or Financial Items -37.2 -25.9 -15.3 -9.6 Operating profit before working capital changes 166.7 117.7 101.0
Slide 26: Utilization of IPO Proceeds
25 Utilization of IPO Proceeds Particulars (Rs. Crs) Original Amount Utilization in FY24 Amount Un-utilized* Repayment and/or prepayment in part or in full, of certain outstanding loans of 144.4 144.4 - the Company Investment in the Subsidiary, UML, for repayment and / or prepayment in part or 23.6
Slide 27: Abbreviations
26 Abbreviations Earnings Before Interest, Taxes, Depreciation and ANDA Abbreviated New Drug Application EBITDA Amortization API Active Pharmaceutical Ingredient FY Financial Year / Fiscal Year B2B Business to Business HPLC High Pressure Liquid Chromatography CAGR Compound Annual Growth Rate IBC Ins
Slide 28: Thank You!
Thank You! Innova Captab Limited : Investor Relations Advisor : http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. Innova Captab Ltd. CIN - U74140MH2010PTC204285 CIN – L24246MH2005PLC150371 Ms. Shaily Patwa / Mr. Shrikant Sangani Mr. Lokesh Bhasin Email – shaily.p@sgapl.n
Slide 29: Q1 FY25 Investor Presentation
Investor Presentation Q1 FY25 Investor Presentation
Slide 30: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 31: Q1FY25 Performance Highlights
Q1FY25 Performance Highlights
Slide 32: MD's Commentary
Performance Highlights 04 MD’s Commentary “For Q1FY25, we reported a total income of Rs 296 crores, a 27% growth compared to same quarter previous year. All business areas are experiencing healthy growth and are expected to maintain this momentum in the coming quarters. Our greenfield plant in Jammu
Slide 33: Financial Highlights
Performance Highlights 05 Financial Highlights Revenue from Operations EBITDA and EBITDA Margin1 PAT and PAT Margin (In Rs Crs) 13.9% 16.7% 15.1% 7.5% 10.9% 10.0% 294.3 262.6 44.3 29.5 43.8 28.7 233.2 32.4 17.6 Q1 FY24 Q4 FY24* Q1 FY25* Q1 FY24 Q4 FY24* Q1 FY25* Q1 FY24 Q4 FY24* Q1 FY25* Geographic
Slide 34: Quarterly Consolidated Profit & Loss Statement
Performance Highlights 06 Quarterly Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) Q1 FY25* Q1 FY24 YoY Q4 FY24* QoQ Revenue from Operations 294.3 233.2 262.6 Other Income 2.1 1.1 5.7 Total Income 296.4 234.4 26.5% 268.3 10.5% Cost of Material Consumed 199.2 166.5 168.3 Employee Cost
Slide 35: Corporate Snapshot
Corporate Snapshot
Slide 36: Innova Captab – At a Glance
Corporate Snapshot 08 Innova Captab – At a Glance Integrated Pharmaceutical Company in India with Presence Across the Pharmaceutical Value Chain 1 Contract Development and Manufacturing 4 Manufacturing Units 190+ 2 Baddi | 1 Dehradun | 1 Taloja CDMO Customers Business 2 Domestic Branded Generics Are
Slide 37: The Evolution
Corporate Snapshot 09 The Evolution Major Events and Milestones 1993 2006 1995 2010 2003 20132005 ▪ Established first manufacturing ▪ Commenced operations at a new ▪ Received GMP Certificate for cephalosporin plant in Baddi, Himachal Pradesh dedicated Cephalosporin block (“C products from the Minist
Slide 38: Key Strengths
Key Strengths
Slide 39: Key Strengths
11 Key Strengths Diversified Product Portfolio 01 04 R&D Centric Organization Deep Engagement with 02 Clients 05 Experienced Promoters and Management Team State of the Art Manufacturing Capabilities 03 06 Consistent Financial Performance
Slide 40: 1. Diversified Product Portfolio
Key Strengths 12 1. Diversified Product Portfolio Presence Across the Pharmaceuticals Value Chain Including Manufacturing, Distribution, Marketing and Exports CDMO Services and Products Domestic Branded Generics Sharon Bio Medicine Ltd • Comprehensive CDMO Formulation capabilities offering • Consist
Slide 41: 2. Deep Engagement with Clients
Key Strengths 13 2. Deep Engagement with Clients Developed Strong Relationships across the Indian Pharmaceutical Industry Revenue from CDMO Revenue from CDMO Revenue from CDMO Number of CDMO Revenue from CDMO Customers > 10 customers with customers < 5 Customers years relationship1 5-10 years1 years
Slide 42: 3. State of the Art Manufacturing Capabilities
Key Strengths 14 3. State of the Art Manufacturing Capabilities Our Manufacturing Capacity Helps Us to Provide Customers with Large Volumes and Satisfy their Requirements Second highest Fixed Asset Turnover ratio Ranked third among CDMO players in terms of tablet and and ROCE among the CDMO formulat
Slide 43: 3. Long Runway of Growth
Key Strengths 15 3. Long Runway of Growth Baddi Plant Dehradun | Taloja Plant Greenfield project at Jammu Capacity 45% - 50% Utilization 50% -60% FY24 revenue Un-utilized Optimum FY24 revenue Un-utilized Optimum Utilization FY23 FY25- to Rampup- 2-4 Optimum Rs 865 crs Utilization in Rs 190 crs* in c
Slide 44: 4. R&D Centric Organization
Key Strengths 16 4. R&D Centric Organization R&D is Critical to Maintaining Our Competitive Position and Addressing Changing Consumer and Industry Trends Dedicated R&D laboratory and pilot equipment located at Baddi, Himachal Pradesh which is 1 recognized by the DSIR for in-house R&D work Equipped w
Slide 45: 5. Experienced Promoters and Management Team
Key Strengths 17 5. Experienced Promoters and Management Team Qualified and Experienced Management Team Manoj Kumar Lohariwala Vinay Kumar Lohariwala Jayant Vasudeo Rao Archit Aggarwal Chairman & Whole-time Director Managing Director Whole-time Director Non-Executive Director • Bachelor’s in Commerc
Slide 46: 6. Consistent Financial Performance
Key Strengths 18 6. Consistent Financial Performance Strong Financial Performance with Visible Growth Profile Revenue from operations EBITDA and EBITDA Margin PAT and PAT Margin 13.6% 12.4% 13.3% 15.4% 8.4% 8.0% 7.3% 8.7% 1,081 926 167 94 801 123 68 64 99 411 56 35 FY21 FY22 FY23 FY24 FY21 FY22 FY23
Slide 47: Growth Strategies
Growth Strategies
Slide 48: Key Growth Strategies
Growth Strategies 20 Key Growth Strategies ▪ Establishing Cephalosporin, Penicillin, Penum & BFS blocks to manufacture Tablets, Capsules, Dry Powder Injection, Dry Syrup & BFS at new Greenfield Expansion at Jammu greenfield site in Jammu. Anticipate benefitting from the New Central Sector Scheme for
Slide 49: Historical Financial Highlights
Historical Financial Highlights
Slide 50: Consolidated Profit & Loss Statement
Historical Financial Highlights 22 Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) FY24 FY23 FY22 FY21 Revenue from Operations 1,081.3 926.4 800.5 410.7 Other Income 12.5 9.2 2.9 1.4 Total Revenue 1,093.8 935.6 803.4 412.0 Cost of Materials Consumed 728.3 691.6 617.9 310.7 Employee Co
Slide 51: Consolidated Balance Sheet
Historical Financial Highlights 23 Consolidated Balance Sheet Assets (Rs. Crs) FY24 FY23 FY22 FY21 Equity & Liabilities (Rs. Crs) FY24 FY23 FY22 FY21 Non - Current Assets 741.1 261.9 196.4 99.1 Total Equity 830.9 276.5 208.6 144.8 Property, plant and equipment 291.6 150.1 156.6 76.4 Share Capital 57
Slide 52: Cash Flow Statement
Historical Financial Highlights 24 Cash Flow Statement Particulars (Rs. Crs) FY24 FY23 FY22 FY21 Net Profit Before Tax 129.5 91.8 85.7 46.3 Adjustments for: Non -Cash Items / Other Investment or Financial Items -37.2 -25.9 -15.3 -9.6 Operating profit before working capital changes 166.7 117.7 101.0
Slide 53: Utilization of IPO Proceeds
25 Utilization of IPO Proceeds Particulars (Rs. Crs) Original Amount Utilization in FY24 Amount Un-utilized* Repayment and/or prepayment in part or in full, of certain outstanding loans of 144.4 144.4 - the Company Investment in the Subsidiary, UML, for repayment and / or prepayment in part or 23.6
Slide 54: Abbreviations
26 Abbreviations Earnings Before Interest, Taxes, Depreciation and ANDA Abbreviated New Drug Application EBITDA Amortization API Active Pharmaceutical Ingredient FY Financial Year / Fiscal Year B2B Business to Business HPLC High Pressure Liquid Chromatography CAGR Compound Annual Growth Rate IBC Ins
Slide 55: Thank You!
Thank You! Innova Captab Limited : Investor Relations Advisor : http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. Innova Captab Ltd. CIN - U74140MH2010PTC204285 CIN – L24246MH2005PLC150371 Ms. Shaily Patwa / Mr. Shrikant Sangani Mr. Lokesh Bhasin Email – shaily.p@sgapl.n